{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:05:04Z","timestamp":1790687104065,"version":"4.1.0"},"reference-count":17,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Objective: To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy. Methods: Combi-LLT-ACS (Patients receiving combination lipid-lowering therapy admitted with the acute coronary syndrome) included 125 patients aged 59 (51; 64) years, of whom 67.2% were men. All underwent percutaneous coronary intervention of the IRA; also, all patients had at least one stenosis &lt; 50% in non-IRA, had high compliance with statins, and did not reached LDL-C level of \u22641.4 mmol\/L. Patients underwent Coronary Computed Tomography Angiography (CCTA) to detect vulnerable AP as well as lipid profile and numerous biomarkers: neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), monocyte to high-density lipoprotein ratio (MHR), systemic inflammatory response index (SIRI), matrix metalloprotease type 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1), Galectin-3 (GAL-3), neutrophil gelatinase-associated lipocalin (NGAL), and C-reactive protein (CRP). Thereafter, they were randomized into two groups, Ezetimibe vs. Alirocumab, on the same visit. The follow-up period was 52 weeks. We used the following CCTA criteria to detect vulnerable AP: positive remodeling, napkin-ring sign, spotty calcification, and low-attenuation plaque. Results: One month after ACS, vulnerable APs were observed by CCTA in 56 patients (44.8%). After 52 weeks, 10 (17.9%) patients showed stabilization of previously vulnerable APs or a decrease in the number of AP vulnerability criteria. At week 52, TC and LDL-C levels decreased significantly over time in both groups. Both arms of therapy demonstrated a positive effect on the inflammatory markers and markers of extracellular matrix remodeling. Direct comparison of changes between groups revealed no statistically significant differences in the number of vulnerability criteria (p = 0.930); however, in the group receiving Ezetimibe, we found a statistically significant change over the observation period (p = 0.032). Conclusions: Among patients with ACS, receiving a high-intensity statin in combination with Ezetimibe or Alirocumab prevented the emergence of new vulnerable coronary lesions over 52 weeks. While direct regression of specific vulnerability criteria was not observed, these therapeutic strategies were associated with a reduction in LDL-C and biomarkers of inflammation and extracellular matrix remodeling.<\/jats:p>","DOI":"10.3390\/jcm15197564","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:09:25Z","timestamp":1790683765000},"page":"7564","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial"],"prefix":"10.3390","volume":"15","author":[{"given":"Anna","family":"Kovalskaya","sequence":"first","affiliation":[{"name":"Department of Propedeutic Therapy with Course of Cardiology, Samara State Medical University, Samara 443099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzel","family":"Bikbaeva","sequence":"additional","affiliation":[{"name":"V. Polyakov Samara Regional Clinical Cardiological Dispensary, Samara 443070, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-2976","authenticated-orcid":false,"given":"Dmitry","family":"Duplyakov","sequence":"additional","affiliation":[{"name":"Department of Propedeutic Therapy with Course of Cardiology, Samara State Medical University, Samara 443099, Russia"},{"name":"V. Polyakov Samara Regional Clinical Cardiological Dispensary, Samara 443070, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Duplyakova","sequence":"additional","affiliation":[{"name":"V. Polyakov Samara Regional Clinical Cardiological Dispensary, Samara 443070, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Sukhinina","sequence":"additional","affiliation":[{"name":"V. Polyakov Samara Regional Clinical Cardiological Dispensary, Samara 443070, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1015-3878","authenticated-orcid":false,"given":"Ekaterina","family":"Savinova","sequence":"additional","affiliation":[{"name":"V. Polyakov Samara Regional Clinical Cardiological Dispensary, Samara 443070, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.15829\/1560-4071-2025-6306","article-title":"2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram","volume":"30","author":"Averkov","year":"2025","journal-title":"Russ. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.15829\/1560-4071-2025-6319","article-title":"2024 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation electrocardiogram","volume":"30","author":"Averkov","year":"2025","journal-title":"Russ. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.15829\/1560-4071-2023-5471","article-title":"Disorders of lipid metabolism. Clinical Guidelines 2023","volume":"28","author":"Ezhov","year":"2023","journal-title":"Russ. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.15829\/1560-4071-2022-5282","article-title":"Effect of combined lipid-lowering therapy on atherosclerotic plaque vulnerability in patients with acute coronary syndrome (Combi-LLT ACS): Randomized trial protocol","volume":"27","author":"Kovalskaya","year":"2022","journal-title":"Russ. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome\u2014The ODYSSEY J-IVUS Trial","volume":"83","author":"Ako","year":"2019","journal-title":"Circ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial","volume":"327","author":"Ueki","year":"2022","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cao, Z., Chen, N., Chen, J., Xu, X., Zhang, Z., and Wang, Y. (2025). Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: A systematic review and meta-analysis. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1612095"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12944-021-01528-3","article-title":"Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography","volume":"20","author":"Gao","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study","volume":"147","author":"Romero","year":"2023","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of Dual Lipid-Lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients with Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00210-014-0982-4","article-title":"The influence of ezetimibe on classical and alternative activation pathways of monocytes\/macrophages isolated from patients with hypercholesterolemia","volume":"387","author":"Suchy","year":"2014","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7564\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:46:32Z","timestamp":1790685992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":17,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197564"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197564","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}